Long-chain saturated fatty acids and its interaction with insulin resistance and the risk of nonalcoholic fatty liver disease in type 2 diabetes in Chinese

被引:8
|
作者
Jiang, Li-Peng [1 ]
Sun, Hong-Zhi [2 ,3 ]
机构
[1] Jinzhou Med Univ, Dept Radiat Oncol, Affiliated Hosp 1, Jinzhou, Peoples R China
[2] Jinzhou Med Univ, Dept Gen Surg, Affiliated Hosp 1, Jinzhou, Peoples R China
[3] Jinzhou Med Univ, Key Lab Liaoning Tumor Clin Metabol KLLTCM, Jinzhou, Peoples R China
来源
关键词
myristic acid (14:0); palmitic acid (16:0); IR; NAFLD; T2D; METABOLIC SYNDROME; PALMITIC ACID; MYRISTIC ACID; EPIDEMIOLOGY; ASSOCIATION; PREVALENCE; NAFLD; LIPOTOXICITY; DIAGNOSIS; PATHOLOGY;
D O I
10.3389/fendo.2022.1051807
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: This study aimed to explore relationships between long-chain saturated fatty acids (LSFAs) and nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes (T2D); and whether insulin action had an interactive effect with LSFAs on NAFLD progression. Methods: From April 2018 to April 2019, we extracted the electronic medical records of 481 patients with T2D who meet the inclusion and exclusion criteria from the Second Affiliated Hospital of Dalian Medical University. Ultrasound was used to estimate NAFLD at admission. Logistic regression analysis were used to estimate odds ratios (OR) and 95% confidence intervals (CI). The additive interaction was carried out to estimate interactions between LSFAs and insulin resistance (IR) in NAFLD patients with T2D. Results: Myristic acid (14:0) and palmitic add (16:0) were positively associated with the risk of NAFLD (OR for myristic acid (14:0): 7.516, 3.557-15.882 and OR for palmitic acid (16:0): 4.071, 1.987-8.343, respectively). After adjustment for traditional risk factors, these associations were slightly attenuated but still highly significant. Co-presence of myristic acid (14:0)>72.83 mu mol/L and IR>4.89 greatly increased OR of NAFLD to 9.691 (4.113-22.833). Similarly, copresence of palmitic acid (16:0)>3745.43 mu mol/L and IR>4.89 greatly increased OR of NAFLD to 6.518(2.860-14.854). However, stearic acid (18:0) and risk of NAFLD have no association. Moreover, there was no association between very-long-chain SFAs (VLSFAs) and risk of NAFLD. Discussion: Myristic acid (14:0) and palmitic acid (16:0) were positively associated with the risk of NAFLD in T2D patients in China. High IR amplified the effect of high myristic acid (14:0) and high palmitic acid (16:0) on NAFLD.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] PURIFICATION OF LONG-CHAIN, SATURATED, FREE FATTY-ACIDS
    LONGMUIR, KJ
    HAYNES, S
    JOURNAL OF CHROMATOGRAPHY, 1988, 454 : 438 - 443
  • [32] Nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Cusi, Kenneth
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2009, 16 (02) : 141 - 149
  • [33] Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
    Younossi, Zobair M.
    Gramlich, Terry
    Matteoni, Christi A.
    Boparai, Navdeep
    Mccullough, Arthur J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (03) : 262 - 265
  • [34] Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications
    Targher, Giovanni
    Byrne, Christopher D.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (02): : 483 - 495
  • [35] Role of insulin resistance and diabetes in the pathogenesis and treatment of nonalcoholic fatty liver disease
    Portillo P.
    Yavuz S.
    Bril F.
    Cusi K.
    Current Hepatology Reports, 2014, 13 (2) : 159 - 170
  • [36] Nonalcoholic fatty liver disease and insulin resistance in children
    Song, Kyungchul
    Kim, Ho-Seong
    Chae, Hyun Wook
    CLINICAL AND EXPERIMENTAL PEDIATRICS, 2023, 66 (12) : 512 - 519
  • [37] Association of nonalcoholic fatty liver disease with insulin resistance
    Marchesini, G
    Brizi, M
    Morselli-Labate, AM
    Bianchi, G
    Bugianesi, E
    McCullough, AJ
    Forlani, G
    Melchionda, N
    AMERICAN JOURNAL OF MEDICINE, 1999, 107 (05): : 450 - 455
  • [38] Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides
    Samuel, Varman T.
    Shulman, Gerald I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (19): : 1866 - 1869
  • [39] Nonalcoholic fatty liver disease as a complication of insulin resistance
    Abdelmalek, Manal F.
    Diehl, Anna Mae
    MEDICAL CLINICS OF NORTH AMERICA, 2007, 91 (06) : 1125 - +
  • [40] Nonalcoholic Fatty Liver Disease Lipids and Insulin Resistance
    Berk, Paul D.
    Verna, Elizabeth C.
    CLINICS IN LIVER DISEASE, 2016, 20 (02) : 245 - +